The U.S. Department of Health and Human Services cancelled a $766 million contract with Moderna to develop an mRNA bird flu vaccine, citing safety concerns and under-tested mRNA technology. The decision, criticized by experts like Dr. Ashish Jha and Michael Osterholm, raises concerns about pandemic preparedness. Moderna, while disappointed, reported positive interim results from its Phase 1/2 study. Experts warn that this move jeopardizes the nation's ability to respond effectively to a potential pandemic, emphasizing the need for multiple vaccine platforms.

Prepared by Olivia Bennett and reviewed by editorial team.